An interventional study of Methylcobalamin and Cyanocobalamin group in Vitamin B12 Nutritional Deficiency, sponsored by Fundació Eurecat. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-30.
Sponsored by Fundació Eurecat · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Malnutrition with a site in Spain — 14 open to participants now, 15 under way, none of them phase 3. Malnutrition · Spain.
Among the 68 studies in Malnutrition with a site in Spain, this one is the 31st largest by planned enrollment of the 44 interventional ones that give a count, is one of 6 that started in 2023, is one of 38 with no phase, reaches primary completion later than 6 of the 14 other live ones, and was the 49th registered.
1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.
Browse Malnutrition studies →14 of the 68 studies in Malnutrition with a site in Spain are open now. Recruiting first, the newest first:
Outcomes'10 · Sites in Spain
Ages 18+
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18–64
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Sites in Spain
Ages 18+
Spanish Society of Cardiology · Sites in Spain
Ages 65+
Danone Specialized Nutrition · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 3 · Phase 4 2
First in 2005; this study’s year is marked. 6 started in 2023.
This study's planned enrollment of 54 is below the median of 119 across 844 interventional studies indexed under Malnutrition.
Median enrollment 104 across the 44 interventional studies, 219 across the 24 observational. Of the 41 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 68 have an industry lead sponsor. The 10 most frequent:
Fundació Eurecat is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Fundació Eurecat has 1 study filed under Malnutrition — fewer than ten, so there is no comparison to draw.
2 of the studies in Malnutrition with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04926597Philipp SchuetzEffect of Continued Nutritional Support at Hospital Discharge on Mortality, Frailty, Functional Outcomes and Recovery | 2026-12 |
| NCT05243368Maimónides Biomedical Research Institute of CórdobaEvaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 68 studies in Malnutrition with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Vitamin B12 (B12, Cobalamin) is an essential micronutrient that humans are not capable of synthesizing and therefore must be ingested through food. In nature, B12 is basically only present in foods of animal origin.
B12 deficiency is a clinically important condition that is associated with several metabolic disorders such as megaloblastic anemia, hyperhomocysteinemia, and cardiovascular, cerebrovascular, and neurological disorders. Therefore an optimal intake of B12 is important.
B12 deficiency occurs when B12 stores are depleted due to inadequate dietary intake or impaired absorption of B12. Because B12 is only present in foods of animal origin, following an unbalanced vegetarian diet is associated with increased risk of developing nutritional deficiencies due to the exclusion of meat and fish from their diet, including vitamin B12 deficiency.
There are a variety of forms of vitamin B12 used in vitamin B12 supplements. All these forms share the structure of Cobalamin but contain different ligands. Cyanocobalamin (CNCbl) is a synthetic, stable, and inexpensive form widely used in B12 supplements. MethylCobalamin (MeCbl) is a physiological form of cobalamin, called metabolically active form of vitamin B12. Interest in substituting CNCbl form with the physiological form MCbl has recently increased, assuming that it will be more effective.
The main objective of the study is to evaluate the effect of Methylcobalamin consumption, compared to Cyanocobalamin consumption, on the nutritional status of vitamin B12 in a vegetarian population with marginal vitamin B12 deficiency.
The secondary objectives of the study are to evaluate the effects of Methylcobalamin consumption, compared to Cyanocobalamin consumption, on markers of vitamin B12 deficiency: Holotranscobalamin, Methylmalonic acid, Homocysteine and 4cB12.
During the study there will be 8 visits: a preselection visit (V0; day -7) and 7 study visits during the consumption of the treatments, which will take place on the first day of the study (V1; day 1), after 8 days of treatment (V2; day 8), at 15 days of treatment (V3; day 15), at 29 days of treatment (V4; day 29), at 43 days of treatment (V5; day 43), at 64 days of treatment (V6; day 64), and at 85 days of treatment (V7; day 85).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One capsule daily with 500 µg of methylcobalamin for 12 weeks
Dietary Supplement: Methylcobalamin
One capsule daily with 500 µg of Cyanocobalamin for 12 weeks
Dietary Supplement: Cyanocobalamin group
One capsule daily with microcrystalline cellulose for 12 weeks
Dietary Supplement: Control group
Treatment with Methylcobalamin during 12 weeks
Treatment with Cyanocobalamin during 12 weeks
Treatment with microcrystalline cellulose during 12 weeks
Levels of total vitamin B12 in blood.
Serum total vitamin B12 will be measured by chemiluminescence immunoassay.
Time frame: At day -7 (pre-selection visit), day 8 (visit 2), day 15 (visit 3), day 29 (visit 4), day 43 (visit 5), day 64 (visit 6) and day 85 (visit 7).
Levels of Holotranscobalamin in blood.
Serum Holotranscobalamin will be measured by chemiluminescence immunoassay.
Time frame: At day -7 (pre-selection visit), day 8 (visit 2), day 15 (visit 3), day 29 (visit 4), day 43 (visit 5), day 64 (visit 6) and day 85 (visit 7).
Levels of Methylmalonic acid in blood.
Serum Methylmalonic acid will be measured by Liquid Chromatography coupled to tandem Mass Spectrometry.
Time frame: At day -7 (pre-selection visit), day 8 (visit 2), day 15 (visit 3), day 29 (visit 4), day 43 (visit 5), day 64 (visit 6) and day 85 (visit 7).
Levels of Homocysteine in blood.
Plasma Homocysteine will be measured by Liquid Chromatography coupled to tandem Mass Spectrometry.
Time frame: At day -7 (pre-selection visit), day 8 (visit 2), day 15 (visit 3), day 29 (visit 4), day 43 (visit 5), day 64 (visit 6) and day 85 (visit 7).
Levels of 4cB12 marker.
The 4cB12 marker will be calculated from the blood levels obtained for total vitamin B12, Holotranscobalamin, Methylmalonic acid and Homocysteine using the formula log10((B12 x Holotranscobalamin)/(Methylmalonic acid x Homocysteine)).
Time frame: At day -7 (pre-selection visit), day 8 (visit 2), day 15 (visit 3), day 29 (visit 4), day 43 (visit 5), day 64 (visit 6) and day 85 (visit 7).
Levels of folate in blood.
Serum folate will be measured by chemiluminescence immunoassay.
Time frame: At day -7 (pre-selection visit) and day 85 (visit 7).
Levels of vitamin B6 in blood.
Plasma vitamin B6 will be measured by Ultra High Performance Liquid Chromatography coupled to tandem Mass Spectrometry.
Time frame: At day -7 (pre-selection visit) and day 85 (visit 7).
Health related quality of life.
Health related quality of life will be assessed using the SF-36 questionnaire (36-item short form survey) in Spanish. The SF-36 questionnaire consists of the subscales general health (5 items), mental health (5 items), emotional role (3 items), social function (2 items), vitality (4 items), physical function (10 items), physical role (4 items) and bodily pain (2 items). The items on the scale are ordered in such a way that the higher the score, the higher the state of health. Scores on each of the SF-36 scales range from 0 to 100.
Time frame: At day 1 (visit 1) and day 85 (visit 7).
Dietary habits and caloric intake.
Nutritional habits and caloric intake will be determined based on the results obtained from the 3-day dietary record.
Time frame: At day 1 (visit 1) and day 85 (visit 7).
Consumption of foods with vitamin B12.
Consumption of foods with vitamin B12 by the volunteers will be determined by analyzing the questionnaire on the frequency of consumption of foods with vitamin B12.
Time frame: At day 1 (visit 1), day 8 (visit 2), day 15 (visit 3), day 29 (visit 4), day 43 (visit 5), day 64 (visit 6) and day 85 (visit 7).
Compliance with dietary recommendations.
The adherence to the dietary recommendations by the volunteers will be determined by analyzing the 24h dietary recall.
Time frame: At day 8 (visit 2), day 15 (visit 3), day 29 (visit 4), day 43 (visit 5), and day 64 (visit 6).
Physical activity.
Physical activity will be evaluated through the International Physical Activity Questionnaire (IPAQ)-short for physical activity questionnaire.
Time frame: At day 1 (visit 1) and day 85 (visit 7).
Concomitant medication.
The consumption of concomitant medication by te volunteers will be controlled by the record of concomitant medication in the case report form.
Time frame: At day 1 (visit 1), day 8 (visit 2), day 15 (visit 3), day 29 (visit 4), day 43 (visit 5), day 64 (visit 6) and day 85 (visit 7).
Consumption of food supplements.
The consumption of food supplements by te volunteers will be controlled by the record of food supplements in the case report form.
Time frame: At day 1 (visit 1), day 8 (visit 2), day 15 (visit 3), day 29 (visit 4), day 43 (visit 5), day 64 (visit 6) and day 85 (visit 7).
Body weight.
Body weight measured by standardized method.
Time frame: At day 1 (visit 1) and day 85 (visit 7).
Height.
Height measured by standardized method.
Time frame: At day -7 (pre-selection visit).
Body Mass Index.
Weight and height will be combined to report Body Mass Index in kg/m\^2.
Time frame: At day 1 (visit 1) and day 85 (visit 7).
Age.
The age of the volunteers will be recorded in the case report form.
Time frame: At day -7 (pre-selection visit).
Gender.
The gender of the volunteers will be recorded in the case report form.
Time frame: At day -7 (pre-selection visit).
Intervention compliance.
The intervention compliance by te volunteers will be assessed by counting the number of remaining capsules and applying the formula (Number of capsules consumed/Number of capsules to consume)x100.
Time frame: At day 43 (visit 5) and day 85 (visit 7).
Adverse events.
Possible adverse events derived from taking study's products will be recorded in the case report form.
Time frame: At day 8 (visit 2), day 15 (visit 3), day 29 (visit 4), day 43 (visit 5), day 64 (visit 6) and day 85 (visit 7).
Plan to share: No
Started Sep 2023 (actual). Primary completion is estimated for Sep 2025, 24 months after the start.
Of 393 non-industry interventional studies with no phase under Malnutrition, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 24 months is above that.
Counting every sponsor, half of 419 studies reached it within 22 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mecobalamin
Fundació Eurecat